Exploring the role of a protein in a type of blood vessel inflammation
Novel role of alpha-1 antitrypsin in monocyte-driven disease activity in ANCA-associated vasculitis
This study is looking at how a protein called alpha-1 antitrypsin influences immune cells in people with ANCA-associated vasculitis, a rare autoimmune disease, to help find better ways to treat and predict flare-ups for those affected.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10887261 on NIH RePORTER |
What this research studies
This research investigates how alpha-1 antitrypsin, a protein in the body, affects the activity of immune cells called monocytes in patients with ANCA-associated vasculitis, a rare autoimmune disease. The study aims to understand the underlying mechanisms of this condition and how they can be used to personalize treatment for affected individuals. By utilizing advanced statistical modeling and bioinformatics, the research seeks to identify biomarkers that could predict disease relapses and improve patient outcomes. The principal investigator, Dr. Lynn Fussner, is committed to enhancing care for patients suffering from this challenging disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with ANCA-associated vasculitis who may benefit from improved management strategies.
Not a fit: Patients with other forms of vasculitis or those not diagnosed with ANCA-associated vasculitis may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment strategies for patients with ANCA-associated vasculitis.
How similar studies have performed: Previous research has shown promise in using biomarkers to predict relapses in autoimmune diseases, suggesting that this approach may yield valuable insights.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Fussner, Lynn — Ohio State University
- Study coordinator: Fussner, Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.